Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 22 Genitourinary 12 Tumor-Agnostic 8 Gynecologic 8 Other hematologic neoplasm 6 Thoracic 5 Gastrointestinal 4 Other solid neoplasm 3 Sarcoma 2 CNS 2 Plasma cell 1 NET 1 Myeloid 1 Lymphoid 1 Endocrine 1

Conditions

Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1

Interventions

Dexamethasone 479 Lenalidomide 297 Cyclophosphamide 271 Bortezomib 267 Melphalan 212 Calcium Dobesilate 189 fludarabine phosphate 121 daratumumab 121 Peripheral Blood Stem Cell Transplantation 101 fludarabine 99 carfilzomib 98 Thalidomide 94 pomalidomide 92 Filgrastim 92 Whole-Body Irradiation 88 Mycophenolic Acid 88 Busulfan 80 Tacrolimus 75 Granulocyte Colony-Stimulating Factor 72 dexamethasone acetate 65 ixazomib 62 Cyclosporine 59 dexamethasone 21-phosphate 56 Antilymphocyte Serum 51 auricularum 50 isatuximab 44 Radiotherapy 41 Etoposide 40 Stem Cell Transplantation 39 Methotrexate 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × talazoparib × Plasma cell × Clear all

NCT02693535 2026-05-29

TAPUR

American Society of Clinical Oncology

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡